Swiss company Abionic has launched the new tool, Covid Sequential Organ Failure Assessment (cSOFA) score, which can evaluate the severity of Covid-19.
The cSOFA score assesses the chances of clinical deterioration in Covid-19 patients, aids in triaging and assigning them to the general ward or intensive care units (ICU) on hospital admission and during the stay.
Medical decisions can be made on obtaining a low score to safely discharge the patients from the hospital or move them from the ICU to the general ward.
This also allows freeing up much-needed ICU and hospital capacities.
The tool, obtained the CE mark in Europe, relies on Abionic’s novel biomarker, pancreatic stone protein (PSP).
During the Covid-19 pandemic, patient triage mostly derived from patient age, a criterion at times criticised for its alleged bias.
With the cSOFA score, the focus can now shift from demographic to medical criteria by considering the severity of each case.
Abionic CEO Dr Nicolas Durand said: “Measuring Covid-19 severity and likelihood of clinical deterioration protects hospitals around the globe from preventable overload and makes sure patients are treated according to their needs.
“Our research also indicates that modifications to the cSOFA score may be used as severity measures for other illnesses, such as flu, sepsis and other inflammatory disorders.”
The cSOFA score is an enhanced version of an already used SOFA score. It provides results in only five minutes and needs only 30ul drop of capillary blood.
Even those not medically trained can carry out blood sampling.
This tool can serve as a monitoring parameter during hospital stays to detect deterioration in Covid-19 patients before they show clinical signs.